clinical trial · NCT06045299
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
PresbyopiaNear VisionMiosisEye DiseasesAceclidine+Brimonidine combination ophthalmic solutionAceclidine ophthalmic solutionPlacebo (Vehicle) ophthalmic solution
brief summary
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
started
Sep 27, 2023
primary completion
Aug 19, 2024
completion
Jan 27, 2025
last updated
Mar 3, 2025
detailed description
A multicenter, randomized, double-masked, placebo-controlled efficacy and safety study . To evaluate the efficacy and safety of LNZ101 (Aceclidine 1.75%/Brimonidine 0.08%)/LNZ100 (Aceclidine 1.75%) compared with placebo for the treatment of presbyopia.
official title
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol